Self- and physician-collected high-risk human papillomavirus (HPV) testing to detect high-grade cervical lesions among Thai women

Objective We compared the performance of high-risk human papillomavirus (HPV) messenger RNA testing of physician- and self-collected specimens for detecting histological grade 2 or higher cervical intraepithelial neoplasia (CIN) among women who visited a colposcopy clinic in Thailand. Methods From January 2022 to April 2022, 500 women participated in this cross-sectional multicenter study; 494 had complete data and valid specimen results. The participants were women who attended any one of the 10 participating institutes’ colposcopy clinics due to abnormal cytology, positive high-risk HPV testing, or for follow-up. Participants used a self-sampling Aptima Multitest Swab specimen collection kit to self-collect vaginal samples before physicians biopsied the cervix during the colposcopic examination. The self- and physician-collected specimens were tested for high-risk HPV messenger RNA using Aptima nucleic acid amplification assays. Cervical tissues were collected during colposcopic-directed biopsy from the most severe lesion or a random biopsy and endocervical curettage specimen if no lesion was detected. Results We detected high-risk HPV messenger RNA in 75.4% of self-collected specimens and 70.6% of physician-collected specimens. The prevalence of histological grade 2 or higher CIN from cervical histology was 25.1% (n=124). For self-collected specimens, the sensitivity and specificity of high-risk HPV messenger RNA for grade 2 or higher CIN were 87.0% (95% CI 79.7% to 92.4%; n=108) and 28.5% (95% CI 24.0% to 33.4%). For physician-collected specimens, the sensitivity and specificity of high-risk HPV messenger RNA for grade 2 or higher CIN were 90.2% (95% CI 83.6% to 94.9%; n=112) and 36.1% (95% CI 31.2% to 41.3%). Conclusions Self-collected specimens for high-risk HPV messenger RNA testing demonstrated good sensitivity and negative predictive value for detecting grade 2 or higher CIN in Thai women attending the participating institutes’ colposcopy clinics. Self-collected samples performed similarly to physician-collected ones.

[1]  A. Bhattacharjee,et al.  Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India , 2021, Asian Pacific journal of cancer prevention : APJCP.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  S. Sangrajrang,et al.  National Cervical Cancer Screening in Thailand , 2021, Asian Pacific journal of cancer prevention : APJCP.

[4]  H. Jung,et al.  Self‐obtained vaginal samples for HPV DNA testing to detect HPV‐related cervical disease , 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  P. Bhattarakosol,et al.  Comparison of detection rate of high risk HPV infection between self-collected HPV testing and clinician-collected HPV testing in cervical cancer screening. , 2019, Taiwanese journal of obstetrics & gynecology.

[6]  J. Kimani,et al.  High‐risk HPV‐RNA screening of physician‐ and self‐collected specimens for detection of cervical lesions among female sex workers in Nairobi, Kenya , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[7]  Thaniya Sricharunrat,et al.  Agreement of self- and physician-collected samples for detection of high-risk human papillomavirus infections in women attending a colposcopy clinic in Thailand , 2018, BMC Research Notes.

[8]  N. Phoolcharoen,et al.  Acceptability of Self-Sample Human Papillomavirus Testing Among Thai Women Visiting a Colposcopy Clinic , 2018, Journal of Community Health.

[9]  E. Franco,et al.  HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV‐based primary screening to liquid‐based cytology for cervical cancer , 2017, International journal of cancer.

[10]  Brandy R. Maynard,et al.  The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis , 2016, Sexually Transmitted Infections.

[11]  M. Nygård,et al.  Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme , 2016, PloS one.

[12]  D. Buchwald,et al.  Assessing Acceptability of Self-Sampling Kits, Prevalence, and Risk Factors for Human Papillomavirus Infection in American Indian Women , 2016, Journal of Community Health.

[13]  H. Sriplung,et al.  Low Coverage and Disparities of Breast and Cervical Cancer Screening in Thai Women: Analysis of National Representative Household Surveys. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[14]  T. Wright,et al.  Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. , 2015, Gynecologic oncology.

[15]  M. Zorzi,et al.  Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter , 2015, British Journal of Cancer.

[16]  P. Nilyanimit Comparison of detection sensitivity for human papillomavirus between self-collected vaginal swabs and physician-collected cervical swabs by electrochemical DNA chip. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[17]  M. Boulvain,et al.  HPV self‐sampling as primary screening test in sub‐Saharan Africa: Implication for a triaging strategy , 2014, International journal of cancer.

[18]  L. Elit,et al.  Evaluation of a New APTIMA Specimen Collection and Transportation Kit for High-Risk Human Papillomavirus E6/E7 Messenger RNA in Cervical and Vaginal Samples , 2014, Sexually transmitted diseases.

[19]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[20]  J. Palefsky,et al.  Acceptability of cervical and anal HPV self-sampling in a sample of Hispanic women in Puerto Rico. , 2012, Puerto Rico health sciences journal.

[21]  Y. Qiao,et al.  A cross-sectional study on the acceptability of self-collection for HPV testing among women in rural China , 2012, Sexually Transmitted Infections.

[22]  Joakim Dillner,et al.  Screening and cervical cancer cure: population based cohort study , 2012, BMJ : British Medical Journal.

[23]  M. Hudgens,et al.  Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE study , 2011, International journal of cancer.

[24]  Y. Qiao,et al.  Prevalence of type‐specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self‐collected specimens: Implications for vaginal self‐collection , 2009, International journal of cancer.

[25]  A. Bankfalvi,et al.  Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. , 2008, Oncology reports.

[26]  J. Ferlay,et al.  Worldwide burden of gynaecological cancer: the size of the problem. , 2006, Best practice & research. Clinical obstetrics & gynaecology.

[27]  T. Wright,et al.  HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. , 2000, JAMA.

[28]  J. Pfanzagl On median unbiased estimates , 1972 .

[29]  A. Burchell,et al.  Randomized Intervention of Self-Collected Sampling for Human Papillomavirus Testing in Under-Screened Rural Women: Uptake of Screening and Acceptability. , 2016, Journal of women's health.

[30]  S. Oranratanaphan,et al.  Knowledge, attitudes and practices about the Pap smear among medical workers in Naresuan University Hospital, Thailand. , 2010, Asian Pacific journal of cancer prevention : APJCP.